PDE-5 Inhibitors: Clinical Points

被引：18

作者：

Doumas, Michael ^{[1
]}

Lazaridis, Antonios ^{[1
]}

Katsiki, Niki ^{[1
]}

Athyros, Vasilios ^{[1
]}

机构：

[1] Aristotle Univ Thessaloniki, Propedeut Dept Internal Med 2, GR-54006 Thessaloniki, Greece

来源：

CURRENT DRUG TARGETS | 2015年 / 16卷 / 05期

关键词：

Cardiovascular risk; erectile dysfunction; female sexual dysfunction; phosphodiesterase-5; inhibitors; sildenafil; tadalafil; vardenafil; ONCE-A-DAY; SILDENAFIL CITRATE VIAGRA((R)); ISCHEMIC OPTIC NEUROPATHY; CORONARY-ARTERY-DISEASE; QUALITY-OF-LIFE; ERECTILE DYSFUNCTION; DOUBLE-BLIND; SEXUAL DYSFUNCTION; CARDIOVASCULAR EVENTS; PHOSPHODIESTERASE-5; INHIBITORS;

D O I：

10.2174/1389450115666141111111301

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

Erectile dysfunction is usually of vascular origin and is frequently encountered in men with cardiovascular disease. The introduction of phosphodiesterase-5 inhibitors has revolutionized the management of patients with erectile dysfunction. Currently available phosphodiesterase-5 inhibitors have distinct pharmacokinetic and pharmacodynamic properties, thus permitting for tailoring sexual therapy according to patient characteristics and needs. Phosphodiesterase-5 inhibitors possess vasorelaxing properties and exert systemic hemodynamic effects, which need to be taken into account when other cardiovascular drugs are co-administered. Special caution is needed with alpha-blockers, while the co-administration with nitrates is contra-indicated due to the risk of life-threatening hypotension. This review presents the advent of sexual therapy, describes the mechanism of action and the specific characteristics of commercially available phosphodiesterase-5 inhibitors, summarizes the efficacy and safety of these drugs with special emphasis on the cardiovascular system, and discusses the clinical criteria used for the selection of each drug for the individual patient.

引用

页码：420 / 426

页数：7

共 95 条

[1]

Quality of life and erectile dysfunction [J].

Althof, SE .

UROLOGY, 2002, 59 (06) :803-810

[2]

[Anonymous], 1998, AM J HEALTH-SYST PH, V55, P981

[3]

Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia [J].

Auerbach, SM ;

Gittelman, M ;

Mazzu, A ;

Cihon, F ;

Sundaresan, P ;

White, WB .

UROLOGY, 2004, 64 (05) :998-1003

[4]

Aytac IA, 1999, BJU INT, V84, P50

[5]

Are Phosphodiesterase Type 5 Inhibitors Associated with Vision-Threatening Adverse Events? A Critical Analysis and Review of the Literature [J].

Azzouni, Faris ;

Abu Samra, Khawla .

JOURNAL OF SEXUAL MEDICINE, 2011, 8 (10) :2894-2903

[6]

Basson R, 2003, BJOG-INT J OBSTET GY, V110, P1014, DOI 10.1111/j.1471-0528.2003.02438.x

[7]

Chronic sildenafil improves erectile function and endothelium-dependent cavernosal relaxations in rats:: Lack of tachyphylaxis [J].

Behr-Roussel, D ;

Gorny, D ;

Mevel, K ;

Caisey, S ;

Bernabé, J ;

Burgess, G ;

Wayman, C ;

Alexandre, L ;

Giuliano, F .

EUROPEAN UROLOGY, 2005, 47 (01) :87-91

[8]

Effect of sildenafil on subjective and physiologic parameters of the female sexual response in women with sexual arousal disorder [J].

Berman, JR ;

Berman, LA ;

Lin, H ;

Flaherty, E ;

Lahey, N ;

Goldstein, I ;

Cantey-Kiser, J .

JOURNAL OF SEX & MARITAL THERAPY, 2001, 27 (05) :411-420

[9]

Efficacy of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the International Index of Erectile Function in broad-spectrum populations [J].

Berner, MM ;

Kriston, L ;

Harms, A .

INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2006, 18 (03) :229-235

[10]

Impairment of sexual activity in middle-aged women in Chile [J].

Blümel, JE ;

Castelo-Branco, C ;

Cancelo, MJ ;

Romero, H ;

Aprikian, D ;

Sarrá, S .

MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2004, 11 (01) :78-81

← 1 2 3 4 5 6 7 8 9 10 →